A Phase 3 interventional study of Lebrikizumab in Atopic Dermatitis, sponsored by Eli Lilly and Company. Completed at 321 sites in 16 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-11-05.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing lebrikizumab in Dermatitis, Atopic — 4 open to participants now, 7 under way, 4 of them phase 3. lebrikizumab · Dermatitis, Atopic.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, this one has the largest enrollment, is one of 4 that started in 2020, is one of 17 in phase 3, and was the 8th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →4 of the 24 studies testing lebrikizumab in Dermatitis, Atopic are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Australia and 10 more countries
Ages 6 mo–18 yrs
Forefront Dermatology S.C · Sites in United States
Ages 12+
Almirall, S.A.
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+
By country, each count listing its studies:
lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,153 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 252 across the 24 interventional studies. Of the 17 that completed or were terminated, 13 (76%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 24 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
30 studies in Dermatitis, Atopic by Eli Lilly and Company: 1 open now, 2 under way, 2 of them phase 3. Of 28 finished, 25 (89%) have results posted.
Among the 30 studies in Dermatitis, Atopic by Eli Lilly and Company, this one is the 2nd largest by enrollment, is one of 4 that started in 2020, is one of 21 in phase 3, and was the 18th registered.
Eli Lilly and Company’s Dermatitis, Atopic studies by the year they started, since 2013.
3 of the studies testing lebrikizumab in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06526182Phase 3Almirall, S.A.A Study of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis | 2027-04-25 |
| NCT06906497Johann E Gudjonsson MD PhDLebrikizumab in Moderate-to-severe Atopic Dermatitis | 2027-07 |
| NCT07856134Forefront Dermatology S.CAD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes | 2027-08-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 24 studies testing lebrikizumab in Dermatitis, Atopic, from their registry updates:
Among Eli Lilly and Company’s 30 in Dermatitis, Atopic:
This tab as a report to print or save as PDF → With an account.
This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.
Participants who have completed participation in a Dermira- or Lilly-sponsored lebrikizumab study (parent study), DRM06-AD04 (NCT04146363), DRM06-AD05 (NCT04178967), DRM06-AD06 (NCT04250337), DRM06-AD17 (NCT04250350) or DRM06- AD18 (NCT04626297), will be offered the opportunity to enroll in this study. Participants may either be blinded or not blinded, depending on their parent study assignment.
This study will also be open to an additional approximately 100 participants in the United States (addendum) who have not completed participation in a Dermira- or Lilly-sponsored lebrikizumab study. Treatment will not be blinded.
This study will also include an Addendum to extend the study treatment period by an additional 32 weeks and to add a treatment arm testing dosing every 8 weeks. This Addendum will apply to existing study participants in selected countries. Treatment will not be blinded.
Inclusion Criteria for participants coming from a parent study:
Participants must meet all the following criteria to be eligible for this study:
Exclusion Criteria for participants coming from a parent study:
Participants meeting any of the criteria below will not be included in this study:
Open-Label Addendum Inclusion Criteria:
Participants must meet all the following criteria to be eligible for this study addendum:
Open-Label Addendum Exclusion Criteria:
Participants meeting any of the criteria below will be excluded from this study addendum:
Treatment with any of the following agents within 4 weeks prior to the baseline.
Treatment with the following prior to baseline:
Treatment with the following prior to baseline:
Open-Label Extension Addendum Inclusion Criteria:
Have completed Week 100 of Study KGAA and have not yet completed the safety follow-up visit for the main study.
Open-Label Extension Addendum Exclusion Criteria:
Have initiated treatment with a medication prohibited by Study KGAA before addendum baseline. This includes use of biologics for AD (for example, dupilumab and tralokinumab) during the safety follow-up period of Study KGAA.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
250 milligrams (mg) of Lebrikizumab, subcutaneous injection administered every 4 weeks (Q4W) up to 100 weeks.
Biological: Lebrikizumab
250 mg Lebrikizumab, subcutaneous injection administered every 2 weeks (Q2W) up to 100 weeks.
Biological: Lebrikizumab
250 mg of Lebrikizumab, subcutaneous injection administered every 4 weeks (Q4W) up to 32 weeks.
Biological: Lebrikizumab
250 mg of Lebrikizumab, subcutaneous injection administered every 8 weeks (Q8W) up to 32 weeks.
Biological: Lebrikizumab
Subcutaneous injection
Also known as: LY3650150, DRM06
Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events
Percentage of participants discontinued from study treatment due to adverse events is reported.
Time frame: Baseline to Week 100
Primary Treatment Period: Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 at Week 100
The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis. The IGA is comprised of a 5-point numeric scale ranging from 0 (clear skin) to 4 (severe disease) and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point.
Time frame: Week 100
Primary Treatment Period: Percentage of Participants Achieving Response of Eczema Area and Severity Index-75 (EASI-75) at Week 100
EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity.
Time frame: Week 100
This study consists of 2 parts: * 100-week primary treatment period where participants were assigned to either Lebrikizumab Q4W or Q2W treatment arms. * 32-week open label extension addendum (Lebrikizumab Q4W and Lebrikizumab Q8W)
| Milestone | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W | Open-Label Extension Addendum: Lebrikizumab Q4W | Open-Label Extension Addendum: Lebrikizumab Q8W |
|---|---|---|---|---|
| Started | 141 | 1012 | 0 | 0 |
| Received at least 1 dose of study drug | 141 | 1012 | 0 | 0 |
| Completed | 103 | 675 | 0 | 0 |
| Not completed | 38 | 337 | 0 | 0 |
| Withdrew: Adverse event | 3 | 46 | 0 | 0 |
| Withdrew: Due to epidemic/pandemic | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 47 | 0 | 0 |
| Withdrew: Lost to follow-up | 11 | 61 | 0 | 0 |
| Withdrew: Geopolitical conflict | 1 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 5 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 8 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 12 | 0 | 0 |
| Withdrew: Withdrawal by subject | 18 | 138 | 0 | 0 |
| Withdrew: Sponsor decision | 1 | 14 | 0 | 0 |
| Withdrew: Site closure | 0 | 4 | 0 | 0 |
| Milestone | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W | Open-Label Extension Addendum: Lebrikizumab Q4W | Open-Label Extension Addendum: Lebrikizumab Q8W |
|---|---|---|---|---|
| Started | 0 | 0 | 52 | 51 |
| Received at least one doe of study drug | 0 | 0 | 52 | 51 |
| Completed | 0 | 0 | 51 | 49 |
| Not completed | 0 | 0 | 1 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 1 |
| Withdrew: Protocol deviation | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
Percentage of participants discontinued from study treatment due to adverse events is reported.
| percentage of participants | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W |
|---|---|---|
| Primary Treatment Period: Percentage of Participants Discontinued From Study Treatment Due to Adverse Events | 2.1 | 4.5 |
The IGA measures the investigator's global assessment of the participant's overall severity of their Atopic Dermatitis. The IGA is comprised of a 5-point numeric scale ranging from 0 (clear skin) to 4 (severe disease) and a score is selected using descriptors that best describe the overall appearance of the lesions at a given time point.
| Percentage of participants | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W |
|---|---|---|
| Primary Treatment Period: Percentage of Participants With a Response of Investigator Global Assessment (IGA) Score 0 or 1 at Week 100 | 80.1 | 60.6 |
EASI assesses objective physician estimates of 2 dimensions of atopic dermatitis - disease extent and clinical signs, by scoring the extent of disease (percentage of skin affected: 0 = 0%; 1 = 1-9%; 2 = 10-29%; 3 = 30-49%; 4 = 50-69%; 5 = 70-89%; 6 = 90-100%) and the severity of 4 clinical signs (erythema, edema/papulation, excoriation, and lichenification) each on a scale of 0 to 3 (0 = none, absent; 1 = mild; 2 = moderate; 3 = severe) at 4 body sites (head and neck, trunk, upper limbs, and lower limbs). Half scores are allowed. The final EASI score will be obtained by weight-averaging these 4 scores and will range from 0 to 72. A higher score represents greater disease severity.
| Percentage of participants | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W |
|---|---|---|
| Primary Treatment Period: Percentage of Participants Achieving Response of Eczema Area and Severity Index-75 (EASI-75) at Week 100 | 90.4 | 79.4 |
Collected over Primary Treatment Period: Up to 110 Weeks; Open-Label Extension Addendum: up to 42 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Primary Treatment Period: Lebrikizumab Q4W | 0/141 (0%) | 5/141 (3.5%) | 89/141 (63.1%) |
| Primary Treatment Period: Lebrikizumab Q2W | 2/1,012 (0.2%) | 45/1,012 (4.4%) | 638/1,012 (63%) |
| Open-Label Extension Addendum: Lebrikizumab Q4W | 0/52 (0%) | 0/52 (0%) | 17/52 (32.7%) |
| Open-Label Extension Addendum: Lebrikizumab Q8W | 0/51 (0%) | 0/51 (0%) | 13/51 (25.5%) |
| Event | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W | Open-Label Extension Addendum: Lebrikizumab Q4W | Open-Label Extension Addendum: Lebrikizumab Q8W |
|---|---|---|---|---|
| Food allergyImmune system disorders | 1/141 | 0/1012 | 0/52 | 0/51 |
| CellulitisInfections and infestations | 1/141 | 0/1012 | 0/52 | 0/51 |
| AccidentInjury, poisoning and procedural complications | 1/141 | 0/1012 | 0/52 | 0/51 |
| Hip fractureInjury, poisoning and procedural complications | 1/141 | 2/1012 | 0/52 | 0/51 |
| Multiple injuriesInjury, poisoning and procedural complications | 1/141 | 0/1012 | 0/52 | 0/51 |
| DepressionPsychiatric disorders | 1/141 | 1/1012 | 0/52 | 0/51 |
| AppendicitisInfections and infestations | 0/141 | 2/1012 | 0/52 | 0/51 |
| PneumoniaInfections and infestations | 0/141 | 2/1012 | 0/52 | 0/51 |
| Ankle fractureInjury, poisoning and procedural complications | 0/141 | 2/1012 | 0/52 | 0/51 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/141 | 2/1012 | 0/52 | 0/51 |
| Event | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W | Open-Label Extension Addendum: Lebrikizumab Q4W | Open-Label Extension Addendum: Lebrikizumab Q8W |
|---|---|---|---|---|
| Covid-19Infections and infestations | 26/141 | 159/1012 | 1/52 | 0/51 |
| NasopharyngitisInfections and infestations | 13/141 | 115/1012 | 2/52 | 0/51 |
| Dermatitis atopicSkin and subcutaneous tissue disorders | 9/141 | 70/1012 | 0/52 | 1/51 |
| Upper respiratory tract infectionInfections and infestations | 7/141 | 49/1012 | 1/52 | 0/51 |
| ConjunctivitisInfections and infestations | 3/141 | 39/1012 | 1/52 | 0/51 |
| Oral herpesInfections and infestations | 2/141 | 30/1012 | 0/52 | 0/51 |
| Urinary tract infectionInfections and infestations | 3/141 | 30/1012 | 0/52 | 1/51 |
| Conjunctivitis allergicEye disorders | 4/141 | 29/1012 | 0/52 | 0/51 |
| SinusitisInfections and infestations | 4/141 | 15/1012 | 0/52 | 0/51 |
| HeadacheNervous system disorders | 4/141 | 25/1012 | 1/52 | 1/51 |
All participants who received at least one dose of study drug.
| Age, Continuous(years) | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W | Total |
|---|---|---|---|
| Mean | 34.9 ± 16.96 | 32.5 ± 17.23 | 32.8 ± 17.21 |
| Sex: Female, Male(Participants) | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W | Total |
|---|---|---|---|
| Female | 82 | 513 | 595 |
| Male | 59 | 499 | 558 |
| Race (NIH/OMB)(Participants) | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 16 | 17 |
| Asian | 21 | 199 | 220 |
| Native Hawaiian or Other Pacific Islander | 1 | 9 | 10 |
| Black or African American | 9 | 138 | 147 |
| White | 106 | 610 | 716 |
| More than one race | 3 | 25 | 28 |
| Unknown or Not Reported | 0 | 15 | 15 |
| Region of Enrollment(Participants) | Primary Treatment Period: Lebrikizumab Q4W | Primary Treatment Period: Lebrikizumab Q2W | Total |
|---|---|---|---|
| Singapore | 1 | 7 | 8 |
| United States | 72 | 591 | 663 |
| Ukraine | 5 | 4 | 9 |
| Spain | 0 | 7 | 7 |
| Canada | 14 | 80 | 94 |
| Latvia | 3 | 5 | 8 |
| South Korea | 2 | 25 | 27 |
| Taiwan | 4 | 51 | 55 |
| Poland | 23 | 135 | 158 |
| Mexico | 2 | 2 | 4 |
| Australia | 3 | 23 | 26 |
| Bulgaria | 0 | 10 | 10 |
| France | 1 | 3 | 4 |
| Lithuania | 1 | 12 | 13 |
| Germany | 10 | 52 | 62 |
| Estonia | 0 | 5 | 5 |
Showing the first 100 of 321 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2020 to primary completion in Jul 2024, 49 months.
Results were first posted in Aug 2025, 1 year after primary completion.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 49 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lebrikizumab